Letters to the Editors: Response to Jimenez/Poblet

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

New hair growth from minoxidil and finasteride is not reaching full length, possibly due to slow growth cycles. Users discuss dosing strategies for oral minoxidil to improve efficacy and minimize side effects, with advice against consuming topical minoxidil orally.

Oral minoxidil can cause rare facial bloating, especially at higher doses and in women. Reducing sodium intake, drinking more water, and adjusting the dose can help manage side effects.

Oral minoxidil dosing should be based on body weight to minimize side effects, with higher doses increasing risks like pericardial effusion. Combining oral minoxidil with topical treatments and finasteride can improve hair growth, but regular heart health monitoring is essential.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.